What is the appropriate management for a male patient on low‑dose trazodone for insomnia who is experiencing hot flashes?

Discontinue Trazodone and Transition to Alternative Insomnia Management

You should discontinue trazodone in this male patient experiencing hot flashes, as major clinical practice guidelines explicitly advise against using trazodone for chronic insomnia due to its adverse effect profile outweighing limited efficacy benefits 1, 2.

Primary Recommendation: Stop Trazodone

The 2019 VA/DoD guidelines and 2017 American Academy of Sleep Medicine guidelines both provide clear recommendations against trazodone use for insomnia:

• Systematic reviews show trazodone offers no improvement in sleep efficiency, total sleep time, wake after sleep onset, or sleep onset latency compared to placebo 1
• While trazodone may improve subjective sleep quality, this minimal benefit is outweighed by its adverse effects 1
• The evidence quality is low, with studies averaging only 1.7 weeks duration and follow-up of 1-4 weeks 1

Hot Flashes as an Adverse Effect

Hot flashes in this male patient are likely a serotonergic adverse effect of trazodone. The FDA label does not specifically list hot flashes, but the drug's mechanism as a serotonin reuptake inhibitor can cause autonomic dysregulation 3. While some older research explored trazodone for treating hot flashes in men on androgen deprivation 4, this patient is experiencing them from the medication itself.

Transition Strategy

Taper trazodone gradually to avoid discontinuation syndrome, which includes sweating, dysphoric mood, irritability, agitation, dizziness, and sensory disturbances 3. Do not stop abruptly.

Replace with evidence-based alternatives:

1. First-line: Cognitive Behavioral Therapy for Insomnia (CBT-I) - superior to all pharmacotherapy with sustained long-term benefits and no adverse effects 1

2. If pharmacotherapy needed and patient refuses/cannot access CBT-I:

   • Low-dose doxepin (3-6 mg): Improves sleep latency, total sleep time, and sleep quality with minimal adverse effects at hypnotic doses 1
   • Nonbenzodiazepine BZRAs (zolpidem, zaleplon, eszopiclone): Use lowest effective dose for shortest duration; counsel on parasomnia risks 1

Critical Safety Considerations in Males

Monitor for priapism risk - trazodone carries significant risk of prolonged erections (>4 hours) that can cause permanent erectile tissue damage 3. This is a medical emergency requiring immediate discontinuation and urgent care.

Other trazodone risks to consider:

• QT prolongation and cardiac arrhythmias (including torsade de pointes at doses ≤100 mg) 3
• Orthostatic hypotension and syncope 3
• Hyponatremia, particularly in elderly or volume-depleted patients 3

Clinical Algorithm

1. Immediately begin trazodone taper (reduce by 25-50% every 3-7 days depending on current dose)
2. Initiate CBT-I referral during taper period
3. If CBT-I unavailable/refused AND insomnia significantly impairs function:
   • Consider low-dose doxepin 3-6 mg as bridge therapy
   • Use for shortest duration possible (weeks, not months)
4. Monitor hot flashes - should resolve within days to weeks after trazodone discontinuation

Common Pitfalls to Avoid

• Do not continue trazodone simply because it's commonly prescribed - popularity does not equal evidence-based practice
• Do not switch to antihistamines (diphenhydramine, doxylamine) - these are also not recommended and cause tolerance after 3-4 days 1
• Do not use benzodiazepines - harms substantially outweigh benefits (falls, cognitive impairment, dependency) 1
• Do not abruptly stop trazodone - taper to minimize withdrawal symptoms 3

The hot flashes should resolve spontaneously after trazodone discontinuation, confirming the medication as the causative agent.